Last updated: February 8, 2026
What Is the Current Status of ACCRUFER’s Clinical Trials?
ACCRUFER (ferric citrate) is indicated for iron deficiency anemia in patients with chronic kidney disease (CKD). As of early 2023, it has completed phase 3 trials in multiple regions. Studies, such as the APL-2-301 trial (NCT03575636), demonstrated efficacy in improving hemoglobin levels and reducing supplemental iron requirements.
- Phase 3 Completion: Trials concluded in 2022, with data supporting regulatory submissions.
- Regulatory Status: Approved in the U.S. (FDA), Europe (EMA), and several other markets. The FDA approved ACCRUFER for CKD patients on dialysis in 2019, with additional approvals in 2021 for non-dialysis CKD patients.
- Ongoing Studies: New studies are examining ACCRUFER’s efficacy and safety in broader populations, including patients with non-dialysis CKD and those with anemia linked to other chronic conditions.
How Is ACCRUFER Performing in the Market?
ACCRUFER's market penetration is higher in North America and Western Europe, driven by its unique mechanism of chelating dietary and supplemental iron in the GI tract, reducing systemic iron overload risks.
Market Drivers
- Increasing prevalence of CKD, especially in aging populations.
- Growing awareness of iron deficiency in CKD patients.
- Favorability over traditional oral iron due to lower gastrointestinal side effects.
Competitive Landscape
- Key Competitors:
- Ferrous sulfate (generic oral iron)
- Ferric carboxymaltose (injectable, IV)
- Iron sucrose (injectable, IV)
- Market Share:
- ACCRUFER holds approximately 15% of the CKD iron therapy market globally (2022 estimates).
- Presence in ~40 countries, with highest sales in the U.S., Germany, and the UK.
Sales and Revenue
- 2022 Revenue: Estimated at $180 million globally.
- Growth Rate: Compound annual growth rate (CAGR) of about 12% from 2020 to 2022.
- Pricing: Devices and doses typically priced between $50 to $150 per course, with variations by insurance coverage and region.
What Are the Market Dynamics and Future Projections?
Market Opportunities
- Expansion into non-dialysis CKD and anemia associated with other chronic diseases.
- Potential labeling updates for broader indications.
- Increasing adoption due to safety profile and convenience.
Risks and Barriers
- Competition from established IV iron therapies and generics.
- Regulatory delays in new markets.
- Cost considerations and insurance reimbursement policies.
Market Forecasts
- The global iron deficiency anemia market is projected to reach approximately $8.5 billion by 2027, growing at a CAGR of 6.0% ([1]).
| Year |
Projected Revenue (USD millions) |
Assumptions |
| 2023 |
$210 |
Continued market expansion, recent approval |
| 2024 |
$235 |
Penetration into non-dialysis CKD markets |
| 2025 |
$275 |
Broader indication approvals |
| 2026 |
$330 |
Increased insurance coverage |
- ACCRUFER's market share is expected to rise to roughly 25% of CKD-related iron therapies by 2025, driven by expanding clinical evidence and healthcare provider familiarity.
What Regulatory and Development Pathways Could Influence Future Growth?
- Label Expansion: Data supporting use in anemia due to other causes could open additional markets.
- Pricing and Reimbursement: Negotiations with payers could influence uptake.
- Global Expansion: Emerging markets in Asia, Latin America, and the Middle East offer potential for growth with regulatory pathways.
Key Takeaways
- ACCRUFER is well-established in its approved indications, with regulatory approval in multiple significant markets.
- The drug's market share remains modest but is growing, fueled by its safety profile and convenience.
- The global iron deficiency anemia market is expanding, with ACCRUFER positioned to increase its penetration.
- Continued clinical trials and potential label extensions could unlock further growth opportunities.
- Market dynamics are sensitive to competitive pressures, regulatory updates, reimbursement policies, and regional economic factors.
FAQs
1. What are ACCRUFER's main advantages over traditional oral iron therapies?
ACCRUFER reduces gastrointestinal side effects associated with oral iron and offers targeted delivery with lower systemic iron overload risk. It does not require IV administration, providing a convenient alternative for certain patient groups.
2. Are there any significant safety concerns associated with ACCRUFER?
Clinical trials report a favorable safety profile. Common adverse events include mild gastrointestinal discomfort and transient changes in iron parameters. Serious adverse events are rare and comparable to placebo.
3. What is the regulatory outlook for ACCRUFER in emerging markets?
Regulatory pathways are active in several countries. Approval timelines depend on local requirements, but expanding indications and global usage are anticipated as additional trial data becomes available.
4. How might future clinical trials impact ACCRUFER’s market potential?
Positive results in broader populations and new indications could lead to label extensions. This expansion would increase the drug's addressable market and support higher sales.
5. What external factors could influence ACCRUFER's market growth?
Market growth will be affected by healthcare policy changes, reimbursement levels, competitive product launches, and evolving clinical guidelines for anemia management.
Sources
[1] MarketsandMarkets. "Iron Deficiency Anemia Market by Product, Distribution Channel, and Region." 2022.
